Department of Nephrology, Hypertension, and Rheumatology, University Hospital of Muenster, Muenster, Germany.
Am Heart J. 2013 Sep;166(3):449-56. doi: 10.1016/j.ahj.2013.06.010. Epub 2013 Jul 23.
During the past 10 years, chronic kidney disease (CKD) has been recognized as a major global health problem. Factors leading to decreased renal function are closely related to cardiovascular disease and vice versa. Cardiovascular morbidity and mortality are substantially increased in patients with CKD, even in those with only mild or moderate renal impairment. A better understanding of pathogenesis, risk factors, and genetic conditions is strongly required for more specific treatment strategies in CKD because until now, knowledge is very limited.
The German CAD-REF registry is a prospective observational multicenter national registry. It aims at including >3,300 white patients with angiographically documented coronary artery disease (coronary artery disease [CAD]; ≥50% stenosis in at least 1 coronary artery) being enrolled at 32 centers and assigned to 6 different groups according to their estimated glomerular filtration rate and/or proteinuria. Baseline characteristics, treatment data, and biomaterial including serum, plasma, urine, and DNA samples are collected. Follow-ups are performed at 6, 12, 24, 36, 48, and 60 months.
The CAD-REF registry will establish one of the largest ethnically homogeneous cohorts, to date, of clinically and angiographically well-characterized patients with CAD who have all stages of CKD. This approach offers great opportunities for an improved understanding of the underlying pathophysiologic mechanism and clinical impact of CKD in patients with CAD, especially including the identification of clinically relevant risk factors and (genetic and other bio-) markers as a basis to ameliorate future treatment strategies.
在过去的 10 年中，慢性肾脏病（CKD）已被确认为一个主要的全球健康问题。导致肾功能下降的因素与心血管疾病密切相关，反之亦然。即使在仅有轻度或中度肾功能损害的患者中，CKD 患者的心血管发病率和死亡率也大大增加。为了制定更具针对性的 CKD 治疗策略，强烈需要更好地了解发病机制、危险因素和遗传状况，因为到目前为止，相关知识非常有限。
德国 CAD-REF 登记处是一个前瞻性观察性多中心全国性登记处。它旨在纳入 3300 多名经血管造影证实的冠状动脉疾病（CAD；至少 1 条冠状动脉≥50%狭窄）的白人患者，这些患者在 32 个中心被分为 6 个不同的组，根据其估算的肾小球滤过率和/或蛋白尿进行分组。收集基线特征、治疗数据和生物材料，包括血清、血浆、尿液和 DNA 样本。随访时间为 6、12、24、36、48 和 60 个月。
CAD-REF 登记处将建立迄今为止最大的、种族同质性最高的队列之一，该队列由具有所有 CKD 阶段的临床和血管造影特征良好的 CAD 患者组成。这种方法为更好地了解 CAD 患者 CKD 的潜在病理生理机制和临床影响提供了巨大机会，特别是包括确定临床上相关的危险因素和（遗传和其他生物）标志物，以此改善未来的治疗策略。
